Literature DB >> 16084952

Tissues from population-based cancer registries: a novel approach to increasing research potential.

Marc T Goodman1, Brenda Y Hernandez, Stephen Hewitt, Charles F Lynch, Timothy R Coté, Henry F Frierson, Christopher A Moskaluk, Jeffrey L Killeen, Wendy Cozen, Charles R Key, Limin Clegg, Marsha Reichman, Benjamin F Hankey, Brenda Edwards.   

Abstract

Population-based cancer registries, such as those included in the Surveillance, Epidemiology, and End-Results (SEER) Program, offer tremendous research potential beyond traditional surveillance activities. We describe the expansion of SEER registries to gather formalin-fixed, paraffin-embedded tissue from cancer patients on a population basis. Population-based tissue banks have the advantage of providing an unbiased sampling frame for evaluating the public health impact of genes or protein targets that may be used for therapeutic or diagnostic purposes in defined communities. Such repositories provide a unique resource for testing new molecular classification schemes for cancer, validating new biologic markers of malignancy, prognosis and progression, assessing therapeutic targets, and measuring allele frequencies of cancer-associated genetic polymorphisms or germline mutations in representative samples. The assembly of tissue microarrays will allow for the use of rapid, large-scale protein-expression profiling of tumor samples while limiting depletion of this valuable resource. Access to biologic specimens through SEER registries will provide researchers with demographic, clinical, and risk factor information on cancer patients with assured data quality and completeness. Clinical outcome data, such as disease-free survival, can be correlated with previously validated prognostic markers. Furthermore, the anonymity of the study subject can be protected through rigorous standards of confidentiality. SEER-based tissue resources represent a step forward in true, population-based tissue repositories of tumors from US patients and may serve as a foundation for molecular epidemiology studies of cancer in this country.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16084952     DOI: 10.1016/j.humpath.2005.03.010

Source DB:  PubMed          Journal:  Hum Pathol        ISSN: 0046-8177            Impact factor:   3.466


  29 in total

Review 1.  Moonshot Objectives: Catalyze New Scientific Breakthroughs-Proteogenomics.

Authors:  Karin D Rodland; Paul Piehowski; Richard D Smith
Journal:  Cancer J       Date:  2018 May/Jun       Impact factor: 3.360

2.  Human papillomavirus DNA detection, p16INK4a, and oral cavity cancer in a U.S. population.

Authors:  Brenda Y Hernandez; Charles F Lynch; Owen T M Chan; Marc T Goodman; Elizabeth R Unger; Martin Steinau; Trevor D Thompson; Maura Gillison; Christopher Lyu; Mona Saraiya
Journal:  Oral Oncol       Date:  2019-03-05       Impact factor: 5.337

3.  Feasibility of linking population-based cancer registries and cancer center biorepositories.

Authors:  Margaret E McCusker; Rosemary D Cress; Mark Allen; Allyn Fernandez-Ami; Regina Gandour-Edwards
Journal:  Biopreserv Biobank       Date:  2012-10       Impact factor: 2.300

4.  Tracking and evaluating molecular tumor markers with cancer registry data: HER2 and breast cancer.

Authors:  William F Anderson; Philip S Rosenberg; Hormuzd A Katki
Journal:  J Natl Cancer Inst       Date:  2014-04-28       Impact factor: 13.506

5.  Cancer registries and monitoring the impact of prophylactic human papillomavirus vaccines: the potential role.

Authors:  Mona Saraiya; Marc T Goodman; S Deblina Datta; Vivien W Chen; Phyllis A Wingo
Journal:  Cancer       Date:  2008-11-15       Impact factor: 6.860

6.  Soy consumption and histopathologic markers in breast tissue using tissue microarrays.

Authors:  Gertraud Maskarinec; Eva Erber; Martijn Verheus; Brenda Y Hernandez; Jeffrey Killeen; Suzanne Cashin; J Mark Cline
Journal:  Nutr Cancer       Date:  2009       Impact factor: 2.900

7.  Associations between selected biomarkers and prognosis in a population-based pancreatic cancer tissue microarray.

Authors:  Mikiko Takikita; Sean Altekruse; Charles F Lynch; Mark T Goodman; Brenda Y Hernandez; Mark Green; Wendy Cozen; Myles Cockburn; Maria Sibug Saber; Marie Topor; Chris Zeruto; Behnoush Abedi-Ardekani; Marsha E Reichman; Stephen M Hewitt
Journal:  Cancer Res       Date:  2009-03-10       Impact factor: 12.701

Review 8.  Tissue microarrays as a tool in the discovery and validation of tumor markers.

Authors:  Stephen M Hewitt
Journal:  Methods Mol Biol       Date:  2009

9.  Agreement for tumor grade of ovarian carcinoma: analysis of archival tissues from the surveillance, epidemiology, and end results residual tissue repository.

Authors:  Rayna K Matsuno; Mark E Sherman; Kala Visvanathan; Marc T Goodman; Brenda Y Hernandez; Charles F Lynch; Olga B Ioffe; David Horio; Charles Platz; Sean F Altekruse; Ruth M Pfeiffer; William F Anderson
Journal:  Cancer Causes Control       Date:  2013-02-03       Impact factor: 2.506

10.  Mammographic density and epithelial histopathologic markers.

Authors:  Martijn Verheus; Gertraud Maskarinec; Eva Erber; Jana S Steude; Jeffrey Killeen; Brenda Y Hernandez; J Mark Cline
Journal:  BMC Cancer       Date:  2009-06-13       Impact factor: 4.430

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.